Osteoarthritis biotech Carbylan swings for a $75M IPO

Palo Alto, CA's Carbylan Therapeutics has set terms for an IPO worth $75 million at its midpoint, working to get a treatment for osteoarthritis pain through late-stage development. The company plans to move 5.8 million shares at between $12 and $14 each, setting aside another 870,000 shares for its underwriters and tabbing a maximum deal value of $93.4 million. With the proceeds, Carbylan will pay for the ongoing Phase III studies of Hydros-TA, an injectable treatment for arthritic knee pain. The biotech expects to submit the drug for FDA review next year. Filing

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.